Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adjuvant all-trans retinoic acid plus S-1 vs S-1 after resection of intrahepatic cholangiocarcinoma
ChiCTR2500109145Phase 2Not yet recruiting
- Sponsor
- Third Affiliated Hospital of Naval Medical University
- Start
- Sep 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial in intrahepatic cholangiocarcinoma (ICC) comparing S-1 monotherapy with S-1 plus all-trans retinoic acid (2 arms). Primary endpoint: Disease-free survival. Planned start Sep 2025; status: not yet recruiting.
02
Drugs
tegafurtretinoin
03
Conditions
intrahepatic cholangiocarcinoma (ICC)
Beyond the preview
Go deeper on ChiCTR2500109145.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500109145.